Fig. 3From: A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezilLeast squares mean change from baseline in ADAS-cog13 score. ADAS-cog13 Alzheimer’s Disease Assessment Scale-cognitive subscale, LS least squares, SE standard errorBack to article page